INSMED INC Debt Securities, Available-for-sale, Unrealized Gain
INSMED INC (INSM) reported Debt Securities, Available-for-sale, Unrealized Gain of $400.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-02-19
- INSMED INC debt securities, available-for-sale, unrealized gain for fiscal 2025 was $400.00K, a 33.33% increase from fiscal 2024.
- INSMED INC debt securities, available-for-sale, unrealized gain for fiscal 2024 was $300.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|
| 2025-12-31 | $400.00K 10-K · filed 2026-02-19 | |
| 2024-12-31 | $300.00K 10-K · filed 2026-02-19 | |
| 2023-09-30 | $100.00K 10-Q · filed 2023-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |